A Phase 2 Study of Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in Subjects With Advanced Biliary Tract Carcinoma (BTC)

Trial Profile

A Phase 2 Study of Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in Subjects With Advanced Biliary Tract Carcinoma (BTC)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Capecitabine (Primary) ; Oxaliplatin (Primary) ; Pembrolizumab (Primary)
  • Indications Biliary cancer; Biliary tract disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 14 Jun 2017 Planned initiation date changed from 14 Jun 2017 to 15 Jun 2017.
    • 08 Jun 2017 Planned initiation date changed from 13 Jun 2017 to 14 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top